NO20023780D0 - Dipeptid nitril katepsin K inhibitorer - Google Patents

Dipeptid nitril katepsin K inhibitorer

Info

Publication number
NO20023780D0
NO20023780D0 NO20023780A NO20023780A NO20023780D0 NO 20023780 D0 NO20023780 D0 NO 20023780D0 NO 20023780 A NO20023780 A NO 20023780A NO 20023780 A NO20023780 A NO 20023780A NO 20023780 D0 NO20023780 D0 NO 20023780D0
Authority
NO
Norway
Prior art keywords
inhibitors
dipeptide nitrile
nitrile cathepsin
cathepsin
dipeptide
Prior art date
Application number
NO20023780A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023780L (no
Inventor
Martin Missbach
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20023780D0 publication Critical patent/NO20023780D0/no
Publication of NO20023780L publication Critical patent/NO20023780L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20023780A 2000-02-10 2002-08-09 Dipeptid nitril katepsin K inhibitorer NO20023780L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0003111.2A GB0003111D0 (en) 2000-02-10 2000-02-10 Organic compounds
PCT/EP2001/001359 WO2001058886A1 (en) 2000-02-10 2001-02-08 Dipeptide nitrile cathepsin k inhibitors

Publications (2)

Publication Number Publication Date
NO20023780D0 true NO20023780D0 (no) 2002-08-09
NO20023780L NO20023780L (no) 2002-08-09

Family

ID=9885359

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023780A NO20023780L (no) 2000-02-10 2002-08-09 Dipeptid nitril katepsin K inhibitorer

Country Status (31)

Country Link
US (4) US6642239B2 (pl)
EP (1) EP1254124B1 (pl)
JP (1) JP3942895B2 (pl)
KR (1) KR100544553B1 (pl)
CN (2) CN1183122C (pl)
AR (1) AR029466A1 (pl)
AT (1) ATE402930T1 (pl)
AU (1) AU764334B2 (pl)
BR (1) BR0108118A (pl)
CA (1) CA2396158C (pl)
CO (1) CO5261578A1 (pl)
CZ (1) CZ20022721A3 (pl)
DE (1) DE60135087D1 (pl)
ES (1) ES2310177T3 (pl)
GB (1) GB0003111D0 (pl)
HK (1) HK1050197A1 (pl)
HU (1) HUP0300148A3 (pl)
IL (1) IL150406A0 (pl)
MX (1) MXPA02007768A (pl)
MY (1) MY122826A (pl)
NO (1) NO20023780L (pl)
NZ (1) NZ519940A (pl)
PE (1) PE20020220A1 (pl)
PL (1) PL200119B1 (pl)
PT (1) PT1254124E (pl)
RU (2) RU2293732C2 (pl)
SK (1) SK11462002A3 (pl)
TR (1) TR200201752T2 (pl)
TW (1) TWI258473B (pl)
WO (1) WO2001058886A1 (pl)
ZA (1) ZA200206218B (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
YU66101A (sh) 1999-03-15 2004-07-15 Axys Pharmaceuticals Inc. Nova jedinjenja i kompozicije kao inhibitori proteaze
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
JP2004523506A (ja) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド カテプシン阻害剤としての新規な化合物と組成物
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
CA2460125A1 (en) 2001-09-14 2003-03-27 Aventis Pharmaceuticals Inc. Novel compounds and compositions as cathepsin inhibitors
RU2004117877A (ru) 2001-11-14 2006-01-10 Авентис Фармасьютикалз Инк. (Us) Олигопептиды и композиции, содержащие их, в качестве ингибиторов катепсина s
BRPI0308208B8 (pt) * 2002-03-05 2021-05-25 Axys Pharm Inc compostos inibidores de catepsina cisteína protease e composições farmacêuticas compreendendo os mesmos
WO2004052921A1 (en) * 2002-12-05 2004-06-24 Axys Pharmaceuticals, Inc. Cyanomethyl derivatives as cysteine protease inhibitors
CN100393700C (zh) * 2003-06-30 2008-06-11 麦克弗罗斯特(加拿大)公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
BRPI0412769A (pt) * 2003-07-21 2006-09-26 Novartis Ag combinações de um inibidor de catepsina k e um bisfosfonato no tratamento de métastase óssea, crescimento de tumor e perda óssea induzida por tumor
US20070135448A1 (en) * 2003-11-19 2007-06-14 Martin Missbach Use of cathepsin k inhibitors for treating of severe bone loss diseases
DE602005019971D1 (de) 2004-01-08 2010-04-29 Medivir Ab Inhibitoren von cysteinprotease
JP2008513479A (ja) * 2004-09-16 2008-05-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アテローム性動脈硬化症および他の病理を改善するためのｇ型ペプチドおよび他の薬剤
RU2414236C2 (ru) * 2004-12-06 2011-03-20 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Способ улучшения структуры и/или функций артериол
GB0427380D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
EP1841419A4 (en) * 2005-01-19 2009-02-25 Merck Frosst Canada Ltd INHIBITORS OF CATHEPSIN K AND OBESITY
WO2006076797A1 (en) * 2005-01-19 2006-07-27 Merck Frosst Canada Ltd. Cathepsin k inhibitors and atherosclerosis
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
GB0517637D0 (en) * 2005-08-30 2005-10-05 Novartis Ag Organic compounds
WO2007080884A1 (ja) 2006-01-11 2007-07-19 Seikagaku Corporation シクロアルキルカルボニルアミノ酸エステル誘導体及びその製造方法
JP4047365B2 (ja) 2006-01-11 2008-02-13 生化学工業株式会社 シクロアルカンカルボキサミド誘導体及びその製造方法
JP3975226B2 (ja) * 2006-01-11 2007-09-12 生化学工業株式会社 シクロアルキルカルボニルアミノ酸誘導体及びその製造方法
WO2007137149A2 (en) * 2006-05-22 2007-11-29 Velcura Therapeutics, Inc. Use of cathepsin k antagonists in bone production
GB0614046D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614053D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614044D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
CN101970007A (zh) 2007-06-08 2011-02-09 日本化学医药株式会社 脑动脉瘤的治疗或预防药
BRPI0702541A2 (pt) 2007-06-21 2009-02-10 Petroleo Brasileiro Sa processo de craqueamento catalÍtico para produÇço de diesel a partir de sementes de oleaginosas
US7893067B2 (en) 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
JPWO2009054454A1 (ja) 2007-10-24 2011-03-03 国立大学法人 東京医科歯科大学 カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤
WO2009076490A1 (en) * 2007-12-12 2009-06-18 Velcura Therapeutics, Inc. Use of cathepsin l antagonists in the treatment of bone disease
EP2240491B1 (en) 2008-01-09 2015-07-15 Amura Therapeutics Limited TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
GB0817425D0 (en) * 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors
US20100298507A1 (en) 2009-05-19 2010-11-25 Menschig Klaus R Polyisobutylene Production Process With Improved Efficiencies And/Or For Forming Products Having Improved Characteristics And Polyisobutylene Products Produced Thereby
MX2013013281A (es) 2011-05-16 2013-12-06 Bayer Ip Gmbh Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca.
EP2537532A1 (en) 2011-06-22 2012-12-26 J. Stefan Institute Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
US9593138B2 (en) 2012-10-05 2017-03-14 Wayne State University Nitrile-containing enzyme inhibitors and ruthenium complexes thereof
US9481707B2 (en) 2013-06-14 2016-11-01 Seikagaku Corporation α-oxoacyl amino-caprolactam derivative
EP3009425B1 (en) 2013-06-14 2018-06-06 Seikagaku Corporation Alpha-oxoacylaminocaprolactam

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3467691A (en) 1964-04-22 1969-09-16 Tsutomu Irikura N-(n-acylaminoacyl)-aminoacetonitriles
US5206249A (en) 1991-03-27 1993-04-27 Du Pont Merck Pharmaceutical Company Bis-naphthalimides containing amino-acid derived linkers as anticancer agents
EP0547699A1 (en) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
JP3283114B2 (ja) 1992-09-07 2002-05-20 クミアイ化学工業株式会社 縮合ヘテロ環誘導体及び農園芸用殺菌剤
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
DE69406083T2 (de) 1993-04-28 1998-02-26 Kumiai Chemical Industry Co Aminosäureamide, bakterizide für gartenbau und landwirtschaft sowie herstellungverfahren
JPH09501420A (ja) * 1993-07-30 1997-02-10 スミスクライン・ビーチャム・コーポレイション ３−シアノ−３−（３，４−二置換）フェニルシクロヘキシル−１−カルボキシレート類
JPH09504302A (ja) 1993-11-01 1997-04-28 日本チバガイギー株式会社 エンドセリン・レセプター・アンタゴニスト
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
DE69518631T2 (de) 1994-03-10 2001-01-11 Searle & Co L-n6-(1-iminoethyl)lysin - derivate und ihre verwendung als no-synthase - inhibitoren
US5614649A (en) * 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5977075A (en) * 1995-04-21 1999-11-02 Novartis Ag N-aroylamino acid amides as endothelin inhibitors
WO1997027200A1 (en) 1996-01-26 1997-07-31 Smithkline Beecham Plc Thienoxazinone derivatives useful as antiviral agents
AU3359697A (en) 1996-07-08 1998-02-02 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
PL334516A1 (en) 1996-11-22 2000-02-28 Elan Pharm Inc N-(aryl/heteroaryl/alkylacetyl)amino cid amides, pharmaceutic agent containing them and method of inhibiting eduction and/or synthesis of beta-amyloid peptide using such compounds
GB9723407D0 (en) 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
CN1273444C (zh) 1997-11-05 2006-09-06 诺瓦提斯公司 二肽腈
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
WO2000049007A1 (en) 1999-02-20 2000-08-24 Astrazeneca Ab Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
JP2002537294A (ja) 1999-02-20 2002-11-05 アストラゼネカ アクチボラグ カテプシンｌ及びカテプシンｓの阻害剤としてのジ−及びトリペプチドニトリル誘導体
US6395897B1 (en) 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
YU66101A (sh) 1999-03-15 2004-07-15 Axys Pharmaceuticals Inc. Nova jedinjenja i kompozicije kao inhibitori proteaze
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
AU7490900A (en) * 1999-09-16 2001-04-17 Axys Pharmaceuticals, Inc. Chemical compounds and compositions and their use as cathepsin s inhibitors
JP2001139320A (ja) * 1999-11-05 2001-05-22 Asahi Glass Co Ltd 球状シリカゲルの製造方法
EP1244621B1 (en) * 1999-12-24 2006-09-13 F. Hoffmann-La Roche Ag Nitrile derivatives as cathepsin k inhibitors
US6525036B2 (en) * 2000-01-06 2003-02-25 Merck & Co., Inc. Compounds and compositions as protease inhibitors
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
RU2293732C2 (ru) 2007-02-20
PE20020220A1 (es) 2002-03-25
WO2001058886A1 (en) 2001-08-16
KR20020072310A (ko) 2002-09-14
ES2310177T3 (es) 2009-01-01
ZA200206218B (en) 2003-08-05
EP1254124A1 (en) 2002-11-06
PL357901A1 (pl) 2004-07-26
HUP0300148A3 (en) 2005-04-28
CA2396158C (en) 2010-02-02
BR0108118A (pt) 2003-02-25
EP1254124B1 (en) 2008-07-30
AR029466A1 (es) 2003-07-02
ATE402930T1 (de) 2008-08-15
CN1398260A (zh) 2003-02-19
RU2265601C2 (ru) 2005-12-10
MY122826A (en) 2006-05-31
PT1254124E (pt) 2008-11-03
RU2005108133A (ru) 2006-09-10
TR200201752T2 (tr) 2002-10-21
CZ20022721A3 (cs) 2002-11-13
GB0003111D0 (en) 2000-03-29
NO20023780L (no) 2002-08-09
HUP0300148A2 (en) 2003-05-28
CO5261578A1 (es) 2003-03-31
RU2002123350A (ru) 2004-01-10
PL200119B1 (pl) 2008-12-31
MXPA02007768A (es) 2002-10-11
US6642239B2 (en) 2003-11-04
IL150406A0 (en) 2002-12-01
TWI258473B (en) 2006-07-21
DE60135087D1 (de) 2008-09-11
CA2396158A1 (en) 2001-08-16
US20070191392A1 (en) 2007-08-16
HK1050197A1 (en) 2003-06-13
US20030203919A1 (en) 2003-10-30
CN1636980A (zh) 2005-07-13
KR100544553B1 (ko) 2006-01-24
US20050267129A1 (en) 2005-12-01
JP3942895B2 (ja) 2007-07-11
AU764334B2 (en) 2003-08-14
CN1183122C (zh) 2005-01-05
SK11462002A3 (sk) 2003-01-09
JP2003522764A (ja) 2003-07-29
US20010016207A1 (en) 2001-08-23
AU4642601A (en) 2001-08-20
NZ519940A (en) 2004-02-27

Similar Documents

Publication Publication Date Title
NO20023780D0 (no) Dipeptid nitril katepsin K inhibitorer
CY2012007I1 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
NO20026283L (no) Inhibitorer av kobberholdige aminosydaser
NO20034044D0 (no) Metallproteinase-inhibitorer
EP1272467A4 (en) Cathepsin cysteine PROTEASE INHIBITORS
ATE524441T1 (de) Vla-4-inhibitoren
PT1370553E (pt) Inibidores de rhoquinase
DZ3318A1 (fr) Inhibiteur de proteinase
EE200300439A (et) Metalloproteinaasi inhibiitorid
DE60234125D1 (de) E inhibitoren
NO20034032L (no) Metallproteinase-inhibitorer
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20025786D0 (no) Protaseinhibitorer
NO20025005L (no) Proteaseinhibitorer
DE60132468D1 (de) Alen-lanosterol zyklase inhibitoren
NO20032328D0 (no) Proteaseinhibitorer
AR028075A1 (es) Inhibidores de la peptido-desformilasa
DOP2001000307A (es) Inhibidores de thrombin